Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 1;77(12):1575-1577.
doi: 10.1001/jamaneurol.2020.3115.

Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder

A Sebastian Lopez-Chiriboga  1 , Elia Sechi  2 , Marina Buciuc  2 , John J Chen  2   3 , Sean J Pittock  2   4 , Claudia F Lucchinetti  2 , Eoin P Flanagan  2   4
Affiliations

Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder

A Sebastian Lopez-Chiriboga et al. JAMA Neurol. .

Erratum in

  • Error in Author Name.
    [No authors listed] [No authors listed] JAMA Neurol. 2021 Jun 1;78(6):765. doi: 10.1001/jamaneurol.2021.0783. JAMA Neurol. 2021. PMID: 33818613 Free PMC article. No abstract available.

Abstract

This cohort study reports outcomes of long-term follow-up in patients with myelin oligodendrocyte glycoprotein antibody–associated disorder.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Pittock reported receiving grants, personal fees, and nonfinancial support from Alexion Pharmaceuticals; grants from Grifols and the Autoimmune Encephalitis Alliance; grants, personal fees, nonfinancial support, and other from MedImmune; other support from Astellas; and personal fees from UCB; and having Patent No. 8,889,102 (Application No. 12-678350)—Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia—issued; and Patent No. 9,891,219B2 (Application No. 12-573942)—Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an Individual That Is Aquaporin-4 (AQP4)-IgG Autoantibody Positive—issued. Dr Lucchinetti reported receiving grants from Biogen, National Multiple Sclerosis Society, Kingsland Foundation, and National Institute of Neurological Disorders and Stroke during the conduct of the study. Dr Flanagan reported serving as a site principal investigator for a clinical trial of inebilizumab in neuromyelitis optica spectrum disorder and receiving funding to support the research work from Viela Bio during the conduct of the study. No other disclosures were reported.

Figures

Figure.
Figure.. Temporal Distribution and Types of Attacks, Treatments Used, and Disability at Last Follow-up for Each Patient
Short-term treatments were undertaken within 6 weeks and included 1 or more of corticosteroids (oral/intravenous [IV]), intravenous immunoglobulin (IVIg), or plasma exchange. Maintenance treatments with multiple sclerosis (MS) medications included any current or prior approved MS medications except rituximab and ocrelizumab. Oral immunosuppressants included azathioprine, cyclophosphamide, methotrexate, or mycophenolate mofetil. Twenty-three patients received 1 or more maintenance attack-prevention treatments, including MS medications excluding rituximab/ocrelizumab (n = 6); IVIg (n = 3); oral/intermittent IV steroids (n = 5); rituximab (n = 1); oral immunosuppressants (n = 6); or a combination (n = 14). Of 14 patients who received combination treatment, the combinations included steroids and oral immunosuppressant, 13; steroids and rituximab, 5; steroids and IVIg, 4; rituximab and oral immunosuppressant, 1; and steroids and plasma exchange, 1. Triple combinations were also used: steroids, rituximab, and IVIg, 2; steroids, rituximab, and oral immunosuppressant, 1 (7%). EDSS indicates Expanded Disability Status Scale; NMO, neuromyelitis optica; ON, optic neuritis; TM, transverse myelitis; VFS, visual functional system.
See this image and copyright information in PMC

References

    1. Jurynczyk M, Messina S, Woodhall MR, et al. . Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128-3138. doi:10.1093/brain/awx276 - DOI - PubMed
    1. Cobo-Calvo A, Ruiz A, Maillart E, et al. ; OFSEP and NOMADMUS Study Group . Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018;90(21):e1858-e1869. doi:10.1212/WNL.0000000000005560 - DOI - PubMed
    1. López-Chiriboga AS, Majed M, Fryer J, et al. . Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol. 2018;75(11):1355-1363. doi:10.1001/jamaneurol.2018.1814 - DOI - PMC - PubMed
    1. Ramanathan S, Mohammad S, Tantsis E, et al. ; Australasian and New Zealand MOG Study Group . Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127-137. doi:10.1136/jnnp-2017-316880 - DOI - PMC - PubMed
    1. Jiao Y, Fryer JP, Lennon VA, et al. . Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81(14):1197-1204. doi:10.1212/WNL.0b013e3182a6cb5c - DOI - PMC - PubMed

Publication types

MeSH terms